Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Analysts See India’s Glenmark Patent Suits Signal Of Bold Generics Move (India)

This article was originally published in PharmAsia News

Executive Summary

India's Glenmark Pharmaceuticals appears to be increasing its presence in the generics drug market, as revealed by several patent cases the firm has attracted. Sanofi-Aventis of France and Abbott Laboratories of the U.S. have filed a patent-infringement suit in the U.S. against Glenmark's development of a generic to Tarka (trandolapril; verapamil hydrochloride) for treating hypertension. It was only the second patent suit Glenmark has been involved in recent years, but the company also has two other generics filings in the United States. Some analysts believe the company is making an assertive expansion in the generics business. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC065879

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel